Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 701–800 of 831
Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97
Hattori, T., Wang, M. Y., Corrado, A. D., Gross, S., Fang, M., Bang, I., Roy, N., Berezniuk, I., Donaldson, H., Groff, K. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516627122 · Cited by 3
Decoding the glycan shield: Immune recognition and response to the HIV-1 envelope trimer
Nawaz, F. Z., Adams, T. M., Demirturk, M. E., & Avci, F. Y. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111350 · Cited by 3
“While it is well established that the glycosylation of HIV Env affects the antibody response in infected individuals and that many bnAbs target glycan-dependent epitopes, the contribution of Env glycans to shaping CD4 + T-cell responses has been comparatively underexplored (36–38).”
Integrative Approaches to Study Virus Structures
Stuart, D. I., Oksanen, H. M., & Abrescia, N. G. A. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-65187-8_7 · Cited by 3
Hesselman, M. C., Zeeb, M., Rusert, P., Pasin, C., Mamrosh, J. L., Kariuki, S. M., Pichler, I., Sickmann, M., Kaufmann, M. M., Schmidt, D. G., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.01.004 · Cited by 4
“30 Analysis of the V1 regions of the bnAb-inducer Env panel showed that 6/34 bnAb-inducer Envs (17.6”
InfluentialHoning a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency
Lewis, G. K. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82057 · Cited by 3
Girard, M. P., Grand, R. L., Picot, V., Longuet, C., & Nabel, G. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.024 · Cited by 3
Self-citationBroad Neutralizing Antibodies to HIV Env and Other Complex Viral Antigens from Vaccinated Cows
Heydarchi, B., Salazar-Quiroz, N. A., & Purcell, D. F. J. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000347 · Cited by 2
Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1
Górny, M. K. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1787070 · Cited by 3
“The V2 region is weakly immunogenic due to its exceptional flexibility and the number of glycosylation sites in the hypervariable part of the V2 loop, which may inhibit the recognition of this domain by immune cells.(4,11) Stabilization of the V2 region by adding the BG505 SOSIP.”
BackgroundThe Influence of HIV Envelope Glycosylation on Adaptive Immune Response
Hioe, C. E., Kumar, R., & Hu, S. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_3 · Cited by 4
Zhang, Z., Wei, X., Lin, Y., Huang, F., Shao, J., Qi, J., Deng, T., Li, Z., Gao, S., Li, S., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.07.004 · Cited by 4
Autoantibodies Induced by Chimeric Cytokine-HIV Envelope Glycoprotein Immunogens
Isik, G., van Montfort, T., Chung, N. P. Y., Moore, J. P., & Sanders, R. W. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303401 · Cited by 3
Malaspina, A., Collins, B. S., Dell, A., Alter, G., & Onami, T. M. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0102 · Cited by 3
“27 The glycan recognition residues define conserved motifs that may be critical in immunogen design, and have also been implicated in immune evasion.”
Lu, L., Wei, M., Chen, Y., Xiong, W., Yu, F., Qi, Z., Jiang, S., & Pan, C. (2013) · Microbes and Infection · doi:10.1016/j.micinf.2013.10.001 · Cited by 3
Combined Approaches to Study Virus Structures
Badia-Martinez, D., Oksanen, H. M., Stuart, D. I., & Abrescia, N. G. A. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-6552-8_7 · Cited by 3
de Almeida, D. V., Macieira, K. V., Grinsztejn, B. G. J., Veloso, V. G., & Guimarães, M. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167690 · Cited by 3
Differentiating founder and chronic HIV envelope sequences
Murray, J. M., Maher, S. J., Mota, T. M., Suzuki, K., Kelleher, A. D., & Purcell, D. F. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171572 · Cited by 3
“Envelope is the target for broadly neutralizing antibodies (bNAb), and several conserved tertiary structures on Env have been identified as vulnerable sites for bNAb binding [17, 18].”
BackgroundDoran, R. C., Yu, B., Wright, M., O’Rourke, S. M., Yin, L., Richardson, J. M., Byrne, G., Mesa, K. A., & Berman, P. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02313 · Cited by 3
Li, Y., Zhang, X.-L., Yuan, X., Hou, J.-C., Sang, P., & Yang, L. (2020) · RSC Advances · doi:10.1039/d0ra06416e · Cited by 3
Contribution of rare mutational outcomes to broadly neutralizing antibodies
Feng, A., Hao, Q., & Yeap, L.-S. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022065 · Cited by 3
“allows penetration of the HIV-1 glycan shield [51-53].”
BackgroundChuang, G., Zhou, J., Rawi, R., Shen, C., Sheng, Z., West, A. P., Zhang, B., Zhou, T., Bailer, R. T., Doria‐Rose, N. A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/312579 · Cited by 3
“The final PDB IDs we selected included 5V8L (18) (for PGT145), 3U2S (7) (for PG9), 5VGJ (34) (for VRC38.”
BackgroundResultSelf-citationCryo-EM structure of full-length HIV-1 Env bound with the Fab of antibody PG16Preprint
Pan, J., Peng, H., Chen, B., & Harrison, S. C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/730333 · Cited by 3
“We have observed similar results using PG9 and PGT145, both of which bind, like PG16, at the trimer apex [26-28].”
ResultBrouwer, P. J. M., Antanasijevic, A., Ronk, A. J., Müller-Kräuter, H., Watanabe, Y., Claireaux, M. A. F., Lloyd, N. M., Bijl, T. P. L., Perrett, H. R., Steijaert, T. H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.28.486091 · Cited by 3
“Even though side chains were not explicitly built, the high amount of tyrosine residues were readily discernible on the LAVA01 heavy chain, mediating interactions with glycan residues, similarly to several HIV-1 bNAbs (Lee et al., 2017; McLellan et al., 2011).”
BackgroundSelf-citationMarichannegowda, M. H., Heredia, A., Wang, Y., & Song, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.13.584899 · Cited by 3
Kadam, R. U., Juraszek, J., Brandenburg, B., Garg, D., Zhu, X., Jongeneelen, M. A. C., Schepens, W. B. G., Stoops, B., Vermond, J., Goutier, W., et al. (2025) · npj Viruses · doi:10.1038/s44298-025-00166-1 · Cited by 2
“1 and Supplementary Table 1), although with some exceptions including Abs PG9 58 , C05 59 and PGT145 60 , which have longer HCDR3 loops.”
Self-citationDing, S., Wang, H., Han, Z., & Hong, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1729274 · Cited by 4
“Nevertheless, a subset of infected individuals eventually develop broadly neutralizing antibodies (bNAbs) capable of recognizing glycan-dependent epitopes (128, 129) (Figure 2b).”
Sacks, D., Wiehe, K. J., Morris, L., & Moore, P. L. (2022) · Journal of Virology · doi:10.1128/jvi.00270-22 · Cited by 2
Glycopeptide Mimetics Recapitulate High‐Mannose‐Type Oligosaccharide Binding and Function
Lusvarghi, S., Ghirlando, R., Wong, C., & Bewley, C. A. (2015) · Angewandte Chemie · doi:10.1002/ange.201500157 · Cited by 2
Self-citationGarcía‐Machorro, J., Gutiérrez‐Sánchez, M., Rojas-Ortega, D. A., Bello, M., Andrade-Ochoa, S., Díaz-Hernández, S., Correa‐Basurto, J., & Hernández, S. R. (2023) · RSC Advances · doi:10.1039/d2ra08160a · Cited by 2
Wieczorek, L., Chang, D., Sanders‐Buell, E., Zemil, M., Martinez, E. J., Schoen, J., Chenine, A., Molnar, S., Barrows, B. M., Poltavee, K., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02394-y · Cited by 2
Conformational variability of HIV-1 Env trimer and viral vulnerability
Cao, Y., & Im, W. (2026) · eLife · doi:10.7554/elife.110107.4 · Cited by 3
Nandagopal, P., Bhattacharya, J., Srikrishnan, A. K., Goyal, R., Swathirajan, C. R., Patil, S. A., Saravanan, S., Deshpande, S., Vignesh, R., Solomon, S. S., et al. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001016 · Cited by 3
Anti-Carbohydrate HIV Vaccine Design
Wang, L., Costantino, P., Geng, Y., & Zhang, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_6 · Cited by 3
Self-citationManhas, S., Chau, D., Rempel, C., Clark, B. E., Auyeung, K., & Pantophlet, R. A. (2014) · Virology · doi:10.1016/j.virol.2014.05.034 · Cited by 2
An Introduction to the Current State of HIV Vaccine Research
Regenmortel, M. H. V. V. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s8-e001 · Cited by 2
HIV-1 Vaccine Strategies Utilizing Viral Vectors Including Antigen- Displayed Inoviral Vectors
Hassapis, K., & Kostrikis, L. G. (2014) · Current HIV Research · doi:10.2174/1570162x12666140209135651 · Cited by 5
“The crystal structure of PG9 with the gp120 V1/V2 domain has been achieved, confirming that glycans are required for antibody binding to the epitope, but that this interaction is weak enough to avoid autoreactivity [104].”
BackgroundThe Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies
Haynes, B. F., Saunders, K. O., Kelsoe, G. H., Mascola, J. R., & Nabel, G. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397933-9.00024-2 · Cited by 2
Self-citationVzorov, A. N., & Lv, U. (2017) · Molecular Biology · doi:10.7868/s0026898417060076 · Cited by 2
Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
Shivatare, S. S., Shivatare, V. S., Wu, C., & Wong, C. (2018) · Journal of Visualized Experiments · doi:10.3791/55855 · Cited by 2
Carbohydrate-Based Vaccines against HIV/AIDS
Wang, L. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch006 · Cited by 4
Self-citationAir, G. M., & West, J. T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02532-0 · Cited by 2
Raman, S. C., Mejías‐Pérez, E., Gómez, C. E., García‐Arriaza, J., Perdiguero, B., Vijayan, A., Pérez‐Ruiz, M., Cuervo, A., Santiago, C. A., Sorzano, C. Ó. S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02793 · Cited by 2
“Similar binding assays were performed against other bNAbs such as PG9 (37) and PG16 (38) (quaternary bNAbs directed to the V2 loop region of the HIV-1 envelope), PGT145 (39) (a quaternary bNAb against the V1–V2 region of the GP120 protein) and VRC01 (40) (directed to the CD4 binding site).”
MethodSpecific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance
Pısıl, Y., Yazıcı, Z., Shida, H., Matsushita, S., & Miura, T. (2020) · Pathogens · doi:10.3390/pathogens9030181 · Cited by 4
“The V1/V2 fold, also known as the ‘Greek key’, contains four anti-parallel protein strands (A–D) between strands β2 and β3 of the core gp120 [15].”
BackgroundAhmed, S., Shrivastava, T., Kumar, R., Kumar, M., Banerjee, M., Kumar, N., Bansal, M., Das, S., & Samal, S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129733 · Cited by 4
Wei, C., Ekiert, D. C., Nabel, G. J., & Wilson, I. A. (2013) · Wiley eBooks · doi:10.1002/9781118636817.ch21 · Cited by 2
Self-citationPlant‐Produced Antibodies and Post‐Translational Modification
Loos, A., & Steinkellner, H. (2018) · Wiley eBooks · doi:10.1002/9781118801512.ch9 · Cited by 2
Zhang, S., Wang, W. L., Chen, S., Lu, M., Go, E. P., Steinbock, R. T., Ding, H., Desaire, H., Kappes, J. C., Sodroski, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/288472 · Cited by 2
Xu, Z., Zeng, Q., Yang, D., Sun, X., Wei, D., Jacques Demongeot, A., & Cao, Z. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.07.579394 · Cited by 2
Role of HIV Glycans in Transmission and Immune Escape
Moore, P. L., Murphy, M. K., & Derdeyn, C. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_4 · Cited by 1
Marichannegowda, M. H., Agyekum, G., Aparicio, C., Heredia, A., Wang, Y., & Song, H. (2025) · iScience · doi:10.1016/j.isci.2025.112847 · Cited by 1
Figueroa, D. M., Valencia, T. R., Li, H., & Chen, B. K. (2026) · Journal of Virology · doi:10.1128/jvi.01542-25 · Cited by 2
Arandhara, M., Kumar, Y., Dixit, N. M., & Maiti, P. K. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01051 · Cited by 1
Habib, A., Xu, X., Xie, J., & Zhu, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199828 · Cited by 2
“Among them, gp120 is critically involved in recognizing host receptors by binding to CD4 on T cells [7].”
Upadhyay, A., Seow, J., Alguel, Y., Newman, J., Thakur, N., Hay, A. L., Tam, J. C. H., Nans, A., Orton, R. J., Bailey, D., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003882 · Cited by 2
“However, the light chain also makes minor contacts with HIV-1 Env [32] but there is flexibility in terms of light chain pairing [50].”
NMR as a Tool to Unveil the Molecular Basis of Glycan-mediated Host–Pathogen Interactions
Marchetti, R., Molinaro, A., & Silipo, A. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781849739993-00021 · Cited by 1
Tang, X., Guo, J., Cheng, L., Sun, C., Liu, L., Zuo, T., Wang, H., Chen, L., Zhang, L., & Chen, Z. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.062 · Cited by 1
HIV Glycomics and Glycoproteomics
Bonomelli, C., Crispin, M., Scanlan, C. N., & Doores, K. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_1 · Cited by 2
Lamers, S. L., Fogel, G. B., Nolan, D. J., Barbier, A. E., Rose, R., Singer, E. J., Gonzalez-Perez, M. P., & McGrath, M. S. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0267 · Cited by 1
CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498
Cao, W., Li, B., Liu, H., Cheng, X., Liu, Y., Zhao, X., & Qiao, Y. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198001 · Cited by 1
Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination
Vzorov, A. N., & Lv, U. (2017) · Molecular Biology · doi:10.1134/s0026893317060176 · Cited by 2
From predicting to analyzing HIV-1 resistance to broadly neutralizing antibodiesPreprint
Feldmann, A., & Pfeifer, N. (2015) · doi:10.7287/peerj.preprints.1304v1 · Cited by 1
DISCOVERIES AND APPLICATIONS OF GLYCAN ARRAYS
Wu, C., & Chang, S. (2016) · Wiley eBooks · doi:10.1002/9781119006435.ch15 · Cited by 1
Sulfotyrosine, an interaction specificity determinant for extracellular protein-protein interactionsPreprint
Stewart, V. J., & Ronald, P. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.29.466493 · Cited by 1
Zolla‐Pazner, S., Weiß, S., Itri, V., Pan, R., Jiang, X., Luo, C. C., Morris, L., Malherbe, D. C., Barnette, P. T., Alexander, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-829888/v1 · Cited by 1
Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A virusesPreprint
Moin, S. M., Boyington, J. C., Boyoglu-Barnum, S., Gillespie, R. A., Cerutti, G., Cheung, C. S., Cagigi, A., Gallagher, J. R., Brand, J., Prabhakaran, M. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.11.480115 · Cited by 1
Self-citationConformational variability of HIV-1 Env trimer and viral vulnerabilityPreprint
Cao, Y., & Im, W. (2026) · eLife · doi:10.7554/elife.110107 · Cited by 3
“In simulations, R683 consistently interacted with lipid headgroups in the exoplasmic leaflet, while R707 and R709 interacted with those in the cytoplasmic leaflet, together acting as anchors that secure the TMD within the bilayer.”
Coléon, S., Pathirage, R., Ding, W., Itallie, E. S. V., Mansouri, K., Marchitto, L., Cain, D. W., Lu, X., Kumari, V., Sutherland, L. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728024 · Cited by 2
Self-citationB cell responses against the HIV-1 envelope glycoproteins
Dosenovic, P. (2012) · Figshare
Archary, D. (2011) · ResearchSpace (University of KwaZulu-Natal)
Synthesis of Functional and Variable HIV-1 Envelope Glycoproteins
Clapham, P. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7729-7_4
“infl uenced by determinants in the V3 loop [ 210 , 211 ].”
BackgroundIntrahost evolution of HIV-1 phenotypes
Borggren, M. (2012) · Lund University Publications (Lund University)
ELICITATION AND ENHANCEMENT OF T AND B CELL RESPONSES
Uchtenhagen, H. (2012) · Figshare
Antibody Guided Exploration of V3 Exposure on Subtype C HIV
Manhas, S. (2012) · Summit (Simon Fraser University)
Mechanisms of CD8+ T Cell Mediated Virus Inhibition in HIV-1 Virus Controllers
Payne, T. L. (2014) · DukeSpace (Duke University)
Apuntes sobre la patógenesis del VIH, su terapia y eliminación
Fernández‐Ortega, C., Ramírez, A., Paneque, T., & Casillas, D. (2012) · Biotecnología aplicada
Novel CD4-immunoglobulin fusion proteins as HIV-1 immunotherapeutics
Sojane, K. (2013) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Jacob, R. A. (2014) · Open University of Cape Town (University of Cape Town)
Kimata, J. T., Zhou, P., Liu, L., Wang, W., Yang, L., & Ren, H. (2013)
HIV 2012: Aktuelle Forschungsergebnisse
Behrens, G. M. N. (2012) · Der Internist · doi:10.1007/s00108-011-2973-6
Morales, J. F. (2014) · eScholarship (California Digital Library)
Computational-guided determination of the functional role of 447-52D long CDRH3
Kamau, E. T., Bonneau, R., & Kong, X. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzz007
“These bnAbs use the protruding CDRH3 to reach between glycans located in the V1V2 region of the Env trimer so that the β-strand of the hammerhead can interact with a V2 β-strand by a β-sheet like interaction (McLellan et al., 2011; Pancera et al., 2013).”
BackgroundGradual decrease in the inter-population diversity of HIV-1 Env among group M lineages worldwidePreprint
Han, C., Johnson, J., Dong, R., Kandula, R., Kort, A. J., Wong, M., Yang, T., Breheny, P. J., Brown, G., & Haim, H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/753285
“We observe particularly significant changes in clade B at the trimer apex, a domain targeted by multiple quaternary-specific BNAbs including CAP256-VRC26, PG9, PG16 and PGT145 (46–50).”
BackgroundFisher, K. L. (2017) · ResearchSpace (University of KwaZulu-Natal)
Multiple Mechanisms of HIV-1 resistance to PGT135 in Chinese Subtype B’ Slow ProgressorPreprint
Sun, S., Zou, S., Hu, Y., Liu, Y., Ren, L., Hao, Y., Hu, X., Ruan, Y., Ma, L., Shao, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.22.424087
“more conserved core regions inside provide a scaffold to stabilize the protein structure(20, 21).”
BackgroundAugmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2Preprint
Gao, N., Gai, Y., Meng, L., Wang, C., Wang, W., Li, X., Gu, T., Louder, M. K., Doria‐Rose, N. A., Wiehe, K. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.07.455519
“Like other V2-apex bnAbs (Gorman et al., 2020; Gorman et al., 2016; Lee et al., 2017; McLellan et al., 2011), only one J038 Fab binds to the Env trimer.”
BackgroundSelf-citationAntibodies Targeting the Envelope of HIV-1
Mayr, L. M., & Zolla‐Pazner, S. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch11
ТЕОРЕТИЧЕСКИЕ И ПРИКЛАДНЫЕ ПРОБЛЕМЫ НАУКИ О ЧЕЛОВЕКЕ И ОБЩЕСТВЕ
(МПГУ), М. П. Г. У., Анатольевич, Я. А., Неволина, В. В., университет», Ф. В. «. Г., Сабаненкова, К. А., университет», Ф. В. «. Г., Бартеньева, В. Г., образования, Ф. В. «. Г. У. И. С. П., Каспаров, И. В., Новгороде), С. Г. У. П. С. (. С. В. Г. Н., et al. (2022) · ICSP «NEW SCIENCE» eBooks · doi:10.46916/07042022-1-978-5-00174-518-1
Immune Correlates of Disease Progression in Linked HIV-1 Infection
Tuen, M., Bimela, J. S., Banin, A. N., Ding, S., Harkins, G. W., Weiß, S., Itri, V., Durham, A. R., Porcella, S. F., Soni, S., et al. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pai.1.2020.4
Wang, Y. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717967640.793467424
Ito, Y. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718032489.793482265
Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking
Regenmortel, M. H. V. V. (2019) · Springer eBooks · doi:10.1007/978-3-030-32459-9_9
Ivanochko, D., Fabra-García, A., Teelen, K., van de Vegte‐Bolmer, M., van Gemert, G., Newton, J. C., Semesi, A., de Bruijni, M. H. C., Bolscher, J. M., Ramjith, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4199639
Self-citationFinkelstein, M. T., Miller, E. P., Erdman, M. C., & Fera, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962939
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidatesPreprint
He, W., Ou, T., Skamangas, N. K., Bailey, C. C., Bronkema, N., Guo, Y., Yin, Y., Kobzarenko, V., Zhang, X., Pan, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.07.515497
“Moreover, although their breadth is relatively limited, apex bnAbs are typically more potent than other bnAbs (McLellan et al., 2011; Pancera et al., 2013; Doria-Rose et al., 2014; Doria-Rose et al., 2016).”
BackgroundMirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2023) · doi:10.1158/0008-5472.22400820
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2023) · doi:10.1158/0008-5472.22400820.v1
Carbohydrate‐Based Antiviral Vaccines
Plata, A., & Fernández‐Tejada, A. (2023) · Wiley eBooks · doi:10.1002/9783527831326.ch3
“Specifically, crystal structure studies of the complexes between PG9 and scaffolded V1V2 domains revealed that the antibody interacts with two high‐mannose glycans at N160 and N156/N173 and a connected V1V2‐peptide β ‐strand [65].”
Musharrafieh, R. G., Safonova, Y., Song, G., Roark, R. S., Lee, F.-H., Zhang, S., Hurtado, J., Yong, P., Wang, S., Russell, R. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.21.558743 · Cited by 1
Self-citationGlycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers
Akter, F., & Kumar, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110281
Elite neutralizers: An open eye for HIV vaccine development
Arya, R., Nair, K. S., Kumar, V., Agarwal, V., Das, S., & Kumar, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818851-4.00013-7
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.